CnF-DBS for Levodopa-Resistant FOG
NCT: NCT07781696 · NOT_YET_RECRUITING
Brief Summary
The purpose of this trial is to study the safety, practicality, and effectiveness of deep brain stimulation (DBS) therapy in a brain region called the cuneiform nucleus (CnF) to treat disabling freezing of gait (FOG) in patients with Parkinson's disease (PD) when standard treatments are no longer effective. The study uses either the Medtronic's Percept™ PC or RC systems for DBS therapy. Please note that although the Medtronic systems are FDA-approved for other diseases, they have not been approved for the treatment of FOG in PD and their use for stimulation of the CnF target is experimental.
Frequently Asked Questions
What is CnF-DBS for Levodopa-Resistant FOG?
CnF-DBS for Levodopa-Resistant FOG is a clinical trial registered under NCT07781696. Current status: NOT_YET_RECRUITING.
What is the status of NCT07781696?
The current status of NCT07781696 (CnF-DBS for Levodopa-Resistant FOG) is: NOT_YET_RECRUITING.
When did CnF-DBS for Levodopa-Resistant FOG start?
CnF-DBS for Levodopa-Resistant FOG started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.